Patent Cases To Watch In 2021

by April Breyer Menon | Jan 3, 2021

Venable Fizpatrick partner Ha Kung Wong spoke with Law360 for an article analyzing the patent cases to watch in 2021, including U.S. v. Arthrex, which involves the constitutionality of how administrative patent law judges who preside over inter partes review (IPR) and...

The Leading “Not So Different” Podcast Episodes of 2020

by April Breyer Menon | Dec 30, 2020

The Center for Biosimilars’ “Not So Different” podcast “Biosimilar Law Experts Discuss Potential Bills and Chances for Passage” featuring Venable Fizpatrick’s Ha Kung Wong and April Breyer Menon, was one of the series’...

Opinion: The Year Ahead in Biosimilar Potential

by April Breyer Menon | Dec 29, 2020

Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article discussing what to expect for biosimilars in 2021, including the potential for the first authorized biologics, and the Arthrex v. Smith & Nephew case pending at the...

CfB Board Members Reflect on Year in Biosimilars

by April Breyer Menon | Dec 28, 2020

Venable Fizpatrick partner Ha Kung Wong spoke with The Center for Biosimilars for an article reflecting on the biosimilar market in 2020 and what to expect in 2021, particularly with respect to the BPCIA, which is under review at the Supreme Court. The article by The...

PTAB Extension of Pendency for PGR2019-00062 (Galderma v. Medy-Tox)

by April Breyer Menon | Dec 23, 2020

On December 23, 2020, the PTAB sua sponte extended the pendency of Galderma v. Medy-Tox, PGR2019-00062, after determining good cause existed due to travel restrictions caused by the COVID-19 pandemic. The PGR involves U.S. Patent No. 10,143,728, titled “Long...

Venable’s BiologicsHQ Monthly Injection – November 2020

by April Breyer Menon | Dec 9, 2020

Download PDF Download...

« Older Entries

Next Entries »

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.